WebFeb 24, 2024 · CStone Pharmaceuticals is a China-based investment holding company. Through its subsidiaries, the Company is primarily engaged in development, manufacturing and sales of biopharmaceutical products. Its main products include immuno-oncology drugs and molecularly targeted drugs. The Company conducts its businesses mainly in … WebApr 23, 2024 · CStone Pharmaceuticals (HKEX: 2616) is a biopharmaceutical company focused on developing and commercializing innovative immuno-oncology and precision medicines to address the unmet medical needs ...
PCOM Georgia Med Student Helps Turkish Earthquake Victims
WebMay 28, 2024 · Shanghai - CStone Pharmaceuticals Co., Ltd. ('CStone' or the 'Company', HKEX: 2616) today announced that the company released the pre-clinical data of its three pipeline products, i.e. CS1001 (anti-PD-L1 monoclonal antibody), CS3002 (CDK4/6 selective small molecule inhibitor) and CS3003 (HDAC6 selective small molecule inhibitor), in the … WebOct 12, 2024 · Oktober 2024 /PRNewswire/ -- CStone Pharmaceuticals („CStone" HKEX: 2616) gab heute den Abschluss der Aktienzeichnungsvereinbarung bekannt, durch die … detail shop business plan
CStone Pharmaceuticals (CSPHF) Stock Price, News, Quote
WebCSTONE PHARMACEUTICALS REGISTERED AKTIE Profil - hier finden Sie alle Informationen über CSTONE PHARMACEUTICALS REGISTERED AKTIE wie z.B. … WebFunding. CStone Pharmaceuticals has raised a total of $410M in funding over 2 rounds. Their latest funding was raised on May 9, 2024 from a Series B round. CStone Pharmaceuticals is registered under the ticker HKG:2616 . Their stock opened with HK$12.00 in its Feb 25, 2024 IPO. WebEndo launches new DTC campaign to set men straight on Peyronie's disease. Feb 6, 2024 10:17am. chungs egg roll reviews